Cite

HARVARD Citation

    Lv, H. et al. (2022). Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study. Vaccine. 40 (23), pp. 3263-3271. [Online]. 
  
Back to record